We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genetic Polymorphism Linked to Nicotine Addiction

By Biotechdaily staff writers
Posted on 14 Jul 2003
Researchers have identified a specific genetic polymorphism linked to the metabolism of nicotine that may act to inhibit smokers from quitting but paradoxically also protects against the development of pulmonary emphysema.

Investigators at Keio University (Tokyo, Japan) obtained DNA samples from a group of 203 current or ex-smokers with suspected chronic obstructive pulmonary disease (COPD) and from a control group of 123 healthy non-smokers. More...
Basic lifestyle information, including the number of cigarettes consumed per day, the duration of smoking, and the time elapsed since quitting was compiled. Then CYP2A6 genotypes were determined for all participants.

The results, published in the July 2003 issue of Thorax, revealed that those carrying the CYP2A6del allele seemed to be inhibited from breaking the smoking habit, but that the allele also seemed to protect them against the development of pulmonary emphysema. The percentage of subjects with a CYP2A6del allele was lower in heavy smokers than in light smokers or non-smokers. It was also lower in ex-smokers than in current smokers.

The authors conclude, "These findings suggest that determination of the genotype will be useful in efficiently withdrawing patients from nicotine dependence in smoking cessation protocols with nicotine containing materials, and will give a new insight into the pathogenesis of smoking induced pulmonary emphysema.”




Related Links:
Keio University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.